NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 3 hours 59 min ago
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging (U24 Clinical Trials Not Allowed)
Funding Opportunity RFA-AG-20-043 from the NIH Guide for Grants and Contracts. This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA- supported Alzheimer's Disease Research Centers (ADRCs).
Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-20-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for skills development, particularly short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.
Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PAR-19-093, Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
Notice NOT-AA-19-019 from the NIH Guide for Grants and Contracts
Notice of Intent to Publish a Funding Opportunity Announcement for The National Drug Abuse Treatment Clinical Trials Network (UG1) Clinical Trial Optional
Notice NOT-DA-19-047 from the NIH Guide for Grants and Contracts
Notice of NIAAA's Participation in PAR-19-246 "Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)
Notice NOT-AA-19-015 from the NIH Guide for Grants and Contracts
Notice of Correction to PAR-19-246 "Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)"
Notice NOT-DA-19-044 from the NIH Guide for Grants and Contracts
Notice of Special Interest (NOSI): Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development
Notice NOT-HL-19-695 from the NIH Guide for Grants and Contracts
Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-GM-19-001 from the NIH Guide for Grants and Contracts. Human induced pluripotent stem cells (iPSCs) have been used with great success to mimic the differentiation of a variety of tissues, understand early development and study human diseases. Despite approaches that have made the derivation, growth and differentiation of iPSCs more efficient, there remains significant variability in reprogramming efficacy, genomic integrity and developmental potential of iPSCs derived from a single fibroblast or tissue sample. Thus, iPSCs derived from the same sample may differ in their in vitro growth characteristics and their ability to re-differentiate into the desired tissue type. A variety of issues may affect derivation of the iPSCs and their growth, stability and differentiation, including the specific characteristics of the starting cell or tissue sample (e.g., age of donor, tissue type and anatomical location, physiological and disease state), the methods and protocols used to induce pluripotency (e.g., transcription factors, small molecules, cell fusion), the choice of growth factors and other culture conditions, method of storage of cell lines, etc. Further challenges include growing and maintaining sufficient quantities of iPSC lines in culture without changes in their properties, as well as the ability of multiple investigators to identify and authenticate iPSC lines as part of their research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.
Required Use of the xTRACT System to Prepare Data Tables for Training Grant Research Performance Progress Reports in FY 2020
Notice NOT-OD-19-108 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-TR-19-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.
Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, developmental biology, genetics, immunology, neuroscience, pharmacology, physiology, and technology development. In addition to the laboratory experience, the PRAT program provides a structured training environment with extensive career and professional development, mentoring, and networking opportunities planned and supported by the program.
Notice of Webinar for RFA-DA-20-017 and RFA-DA-20-018, "Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD)
Notice NOT-DA-19-046 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that propose to establish Offices of Sponsored Programs (OSPs) or enhance the services of existing OSPs or similar entities at domestic institutions of higher learning. Program priorities include funding primarily undergraduate institutions with emerging biomedical research and/or undergraduate research training programs.
Notice NOT-OD-19-110 from the NIH Guide for Grants and Contracts
Request for Information (RFI): The NINDS is Soliciting Input on Enhancing Neuroscience Research at Institutions with Emerging Neuroscience Programs
Notice NOT-NS-19-059 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-20-013 from the NIH Guide for Grants and Contracts. NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.
Notice NOT-GM-19-041 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-20-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs
Funding Opportunity RFA-DA-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs
Funding Opportunity PAR-19-281 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).
NIH Funding Opportunities
- Notice of Correction to Application and Submission Information for PAR-18-543 "CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)"
- National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32)
- Notice of Clarification to the Award Budget for PAR-18-894, "Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)"
- Notice of Intent to Publish a Funding Opportunity Announcement for the NIH Common Fund Acute to Chronic Pain Signatures Program: Multisite Clinical Center Acute Pain from Musculoskeletal Trauma or Acute Peri-operative Pain (UM1 Clinical Trial Optional)
- Notice of Change to the Award Budget for PAR-18-802 "Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)".